Chronic Myeloid Leukemia Clinical Trials

330 clinical trials for Chronic Myeloid Leukemia across international registries, including 41 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. — RECRUITING · PHASE2
• Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — RECRUITING · PHASE2
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — RECRUITING
• Second STOP After Pioglitazone Priming in CML Patients — RECRUITING · PHASE2
• Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases — RECRUITING · PHASE2
• Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib — RECRUITING · PHASE2
• Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — RECRUITING · PHASE2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. — RECRUITING · PHASE2
• Asciminib RMP Study — RECRUITING
• A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia — RECRUITING · PHASE1
• Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide — RECRUITING · PHASE1
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — RECRUITING · PHASE1
• Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia — RECRUITING
• Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase — RECRUITING
• A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) — RECRUITING · PHASE1
• Selumetinib and Azacitidine in High Risk Chronic Blood Cancers — RECRUITING · PHASE1
• Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor — RECRUITING · PHASE2
• Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL — RECRUITING · PHASE1
• Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies — RECRUITING · PHASE1
• Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network — RECRUITING
• PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML — RECRUITING · PHASE2
• Study of Olverembatinib (HQP1351) in Patients With CP-CML — RECRUITING · PHASE3
• The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP — RECRUITING
• Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial — RECRUITING · PHASE2
• Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia — RECRUITING · NA
• Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia — RECRUITING
• TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients — RECRUITING · PHASE2
• Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial — RECRUITING
• CML Pediatric ITK Response According to Molecular Identification at Diagnosis — RECRUITING
• Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen — RECRUITING · PHASE2
• Vitamin A and D Supplementation in Allogeneic HCT — RECRUITING · PHASE2
• Chronic Myeloid Leukemia (CML) Real-Life Database — RECRUITING
• International Chronic Myeloid Leukemia Pediatric Study — RECRUITING
• A PHASE 1A/1B STUDY OF ELVN-001 FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA — RECRUITING · PHASE1
• A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) — RECRUITING · PHASE1
• Italian Treatment Free Remission Registry — RECRUITING
• AN OPEN-LABEL, MULTICENTRE, PHASE 1B/2 STUDY OF SAFETY AND EFFICACY OF KRT-232 COMBINED WITH A TYROSINE KINASE INHIBITOR (TKI) IN PATIENTS WITH RELAPSED OR REFRACTORY PH+ CHRONIC MYELOID LEUKEMIA (CML) — RECRUITING · PHASE1
• A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES (OPTIC) — RECRUITING · PHASE2
• A PHASE 1B DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY FOR THE COMBINATION OF DASATINIB (BMS-354825) PLUS NIVOLUMAB (BMS-936558) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) — RECRUITING · PHASE1
• A MULTI-CENTER, OPEN LABEL, NON-CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP) OR WITH PH+ CML IN CP OR ACCELERATED PHASE (AP) RESISTANT OR INTOLERANT TO EITHER IMATINIB OR DASATINIB — RECRUITING · PHASE2
• PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT — COMPLETED · PHASE2
• PHASE II MULTICENTER STUDY OF P210-B3A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT — COMPLETED · PHASE2
• Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) — COMPLETED · PHASE2
• A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921 — TERMINATED · PHASE2
• Allogeneic iNKT Cell Therapy (agenT-797) After SCT — NOT_YET_RECRUITING · PHASE1
• A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region — NOT_YET_RECRUITING
• Natural Killer Cells and Bortezomib to Treat Cancer — COMPLETED · PHASE1
• Study of CD38 and CD56 in Chronic Myeloid Leukemia — NOT_YET_RECRUITING

Refine this search